

## IMMUNOBIOLOGICS

IMMUNOBIOLOGIC	PRIMARY IMMUNIZATION SCHEDULE	BOOSTER SCHEDULE	COMMENTS AND CONTRAINDICATIONS
<p>Meningococcal Vaccine, Inactivated Polyvalent Polysaccharide (MPSV4)</p> <p><b>Menomune®</b> A/C/Y/W-135 Sanofi Pasteur</p>	<p><b>Selected children aged 2 years and over and adults<sup>1,2</sup></b></p> <p>First: 0.5 mL Subcutaneously (SC)</p> <p><sup>1</sup> Meningococcal conjugate vaccine is preferred over MPSV4 for persons aged 2-55 years if not contraindicated. MPSV4 should be used for persons aged 56 years and older who need meningococcal vaccine.</p> <p><sup>2</sup> MPSV4 may be recommended for children age 3-23 months under special circumstances. These children should get 2 doses, 3 months apart. Consult with the LA County Immunization Program's medical director. (See Comments and Contraindications column for additional information.)</p>	<p><b>Selected children and adults</b></p> <p>Dose: 0.5 mL SC if indicated<sup>3</sup> (See Revaccination in the Comments and Contraindications column.)</p> <p><sup>3</sup> <b>Persons 7 years or older</b> at prolonged increased risk should be revaccinated 5 years after their previous meningococcal vaccine</p> <p><b>Children 2-6 years</b> at prolonged increased risk should be revaccinated 3 years after their primary meningococcal vaccine</p> <p>Persons who remain in an increased risk group indefinitely should continue to be revaccinated at 5-year intervals</p> <p>Meningococcal conjugate vaccine (MCV4) is normally preferred for persons aged 2-55 years.</p> <p>Revaccinate persons aged 56 years or older with MPSV4 if revaccination is indicated.</p>	<p>For persons 2-55 years of age use of meningococcal conjugate vaccine (MCV4) is preferred over meningococcal polysaccharide vaccine (MPSV4). Use meningococcal polysaccharide vaccine (MPSV4) for persons age 56 years and older.</p> <p><b>Meningococcal Vaccination Indications</b> See Meningococcal Conjugate Vaccine (MCV4)</p> <p>MPSV4 is not recommended for children aged under 2 years because it is relatively ineffective and offers a short duration of protection. However, MPSV4 may be recommended for children age 3-23 months under special circumstances. Serogroup A meningococcal polysaccharide vaccine, given as MPSV4, is immunogenic in children as young as 3 months of age, although the immune response is not comparable to that seen in older children and adults. For children younger than 18 months of age, 2 doses administered 3 months apart have been given for control of epidemics caused by serogroup A, although data regarding the efficacy of this schedule are not available. Serogroup A is a rare cause of invasive meningococcal disease in the United States. Response is poor to the other polysaccharides in MPSV4 when administered to infants younger than 24 months of age.</p> <p><b>Revaccination Recommendations:</b> See Meningococcal Conjugate Vaccine (MCV4)</p> <p>0</p> <p><b>Adverse Reactions:</b> Localized pain and erythema at injection site, transient fever; headache and malaise</p> <p><b>Precautions &amp; Contraindications:</b></p> <ul style="list-style-type: none"> <li>• Hypersensitivity to any vaccine component contraindicates vaccination.</li> <li>• Moderate or severe acute illness is a precaution for vaccination until illness improved.</li> </ul>